ResearcherSichuan UniversityActive in the last 2 years

Chen Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8408-0906; OpenAlex author ID A5101410658. Sources: OpenAlex.

Their work

Papers: 6
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 22

Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 6

Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824 ↗
RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1 ↗
A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac146 ↗
A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Co-author DOI 10.1177/10732748221141233 ↗
Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarc… Co-author DOI 10.1186/s12885-021-08275-9 ↗
Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally A… Co-author DOI 10.21203/rs.3.rs-809969/v1 ↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ke Cheng · 5 shared papers, 2021–2026 · strength 0.84
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146 ↗
- Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233 ↗
Junjie Xiong · 3 shared papers, 2023–2026 · strength 0.54
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Dan Cao · 3 shared papers, 2023–2026 · strength 0.54
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Dan Cao · 3 shared papers, 2021–2022 · strength 0.52
- Paper Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced… DOI 10.1186/s12885-021-08275-9 ↗
- Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233 ↗
- Paper Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiothera… DOI 10.21203/rs.3.rs-809969/v1 ↗
Yi Cheng · 3 shared papers, 2022–2026 · strength 0.52
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Zixing Huang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chenyan Zhang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Yi Zhang · 1 shared paper, 2026 · strength 0.19
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
Bole Tian · 1 shared paper, 2026 · strength 0.19
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
Wanrui Lv · 1 shared paper, 2023 · strength 0.18
- Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146 ↗
Bing Peng · 1 shared paper, 2022 · strength 0.16
- Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233 ↗
Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaoying Li · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Huanji Xu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bole Tian · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Rui Wang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bo Chen · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Zheng Wang · 1 shared paper, 2021 · strength 0.13
- Paper Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiothera… DOI 10.21203/rs.3.rs-809969/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.